Profile data is unavailable for this security.
About the company
Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. It operates through two segments: MedSurg and Neurotechnology, and Orthopedics and Spine. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties. Stryker is also engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. It also offers Fortress, a modular wall system for hospitals and ambulatory surgery centers.
- Revenue in USD (TTM)20.96bn
- Net income in USD3.36bn
- Incorporated1946
- Employees52.00k
- LocationStryker Corp1941 STRYKER WAYPORTAGE 49002United StatesUSA
- Phone+1 (269) 385-2600
- Fax+1 (269) 385-1062
- Websitehttps://www.stryker.com/
Mergers & acquisitions
Acquired company | SYK:NYQ since announced | Transaction value |
---|---|---|
Serf SAS | 15.22% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Becton Dickinson and Co | 19.72bn | 1.36bn | 66.26bn | 73.00k | 48.80 | 2.60 | 18.13 | 3.36 | 4.70 | 4.54 | 67.74 | 88.32 | 0.3633 | 3.37 | 7.93 | 270,082.20 | 2.54 | 2.37 | 2.94 | 2.70 | 41.25 | 45.78 | 6.99 | 6.95 | 0.9705 | 6.91 | 0.4126 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
Medtronic PLC | 32.36bn | 3.68bn | 98.89bn | 95.00k | 27.90 | 2.01 | 15.58 | 3.06 | 2.76 | 2.76 | 24.34 | 38.29 | 0.3578 | 2.11 | 5.34 | 340,673.70 | 4.09 | 4.57 | 4.61 | 5.14 | 65.73 | 66.75 | 11.44 | 13.49 | 1.55 | 9.73 | 0.3317 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
Boston Scientific Corporation | 14.71bn | 1.77bn | 112.34bn | 48.00k | 63.80 | 5.64 | 37.71 | 7.64 | 1.20 | 1.20 | 9.99 | 13.56 | 0.4229 | 1.95 | 6.72 | 306,395.80 | 5.09 | 2.50 | 5.90 | 2.91 | 69.46 | 68.84 | 12.05 | 6.47 | 1.14 | 5.43 | 0.3449 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
Stryker Corp | 20.96bn | 3.36bn | 128.19bn | 52.00k | 38.46 | 6.69 | 29.19 | 6.12 | 8.75 | 8.75 | 54.57 | 50.33 | 0.55 | 1.61 | 6.27 | 403,134.60 | 8.82 | 6.60 | 10.60 | 7.84 | 64.01 | 63.99 | 16.03 | 13.13 | 0.9872 | -- | 0.4016 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
Intuitive Surgical, Inc. | 7.32bn | 1.99bn | 154.74bn | 13.68k | 78.72 | 11.08 | 62.48 | 21.14 | 5.54 | 5.54 | 20.41 | 39.36 | 0.5068 | 2.19 | 7.13 | 535,134.60 | 13.88 | 12.42 | 15.39 | 13.83 | 66.43 | 67.60 | 27.38 | 26.31 | 4.61 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
Abbott Laboratories | 40.33bn | 5.63bn | 179.53bn | 114.00k | 32.05 | 4.63 | 20.24 | 4.45 | 3.22 | 3.22 | 23.06 | 22.31 | 0.5514 | 2.67 | 6.39 | 353,736.80 | 7.70 | 7.72 | 9.60 | 9.39 | 55.25 | 56.73 | 13.96 | 14.39 | 1.11 | 22.29 | 0.272 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
Danaher Corp | 23.74bn | 4.07bn | 181.11bn | 61.00k | 44.85 | 3.39 | 28.91 | 7.63 | 5.45 | 5.90 | 31.84 | 72.16 | 0.2818 | 3.28 | 6.11 | 389,131.20 | 4.83 | 5.93 | 5.36 | 6.56 | 58.39 | 58.79 | 17.14 | 19.11 | 1.51 | 21.68 | 0.2536 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 29.98m | 7.87% |
Greenleaf Asset Management, Inc.as of 09 May 2024 | 21.05m | 5.53% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 17.20m | 4.52% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 14.35m | 3.77% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 11.41m | 3.00% |
Wellington Management Co. LLPas of 31 Mar 2024 | 10.84m | 2.85% |
Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 9.98m | 2.62% |
Fundsmith LLPas of 31 Mar 2024 | 7.26m | 1.91% |
Geode Capital Management LLCas of 31 Mar 2024 | 6.58m | 1.73% |
Wellington Management International Ltd.as of 31 Mar 2024 | 5.52m | 1.45% |